inclusion criteria: 1. ability to understand and the willingness to sign a written informed consent document. 2. individuals aged ≥ 18 years of all races and ethnic groups. 3. must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov- 2 infection within the past 14 days 4. not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s). 5. must meet at least one of the following clinical stratifications: 1. have at least 1 minor criterion per ats criteria (refer to appendix a), or 2. have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography \[ct\]), or 3. high risk for poor outcome, as defined by any one of the following: i. age ≥ 60 years old ii. underlying medical comorbidities, defined as: * serious cardiovascular disease * poorly controlled diabetes (i.e., a1c levels \>7%) * chronic kidney disease requiring dialysis * significant liver disease (pugh-child b or c) * severe obesity (body mass index \[bmi\] ≥ 40) * chronic respiratory disease (e.g., copd) * hypertension, defined as blood pressure ≥ 140 / 90 mmhg iii. solid organ or stem cell transplant recipient iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. receipt of biologic agent or prednisone \> 0.5 mg/kg/day (or equivalent) 6. patient must be within 5 days of symptom onset, as determined by clinical team. 7. participants with preexisting auditory damage are allowed. 8. participants with a history of epilepsy are allowed. 9. female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug. 10. focbp must agree to use highly-effective method(s) of contraception (appendix b) during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for \>1 year without an alternative medical cause. 11. male participants must agree to use an adequate method of contraception (appendix b) starting with the first dose of study therapy through at least 1 months after the last dose of study drug. 12. participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.

inclusion criteria: 1. ability to understand and the willingness to sign a written informed consent document. 2. individuals aged ≥ 18 years of all races and ethnic groups. 3. must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov- 2 infection within the past 14 days 4. not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s). 5. must meet at least one of the following clinical stratifications: 1. have at least 1 minor criterion per ats criteria (refer to appendix a), or 2. have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography \[ct\]), or 3. high risk for poor outcome, as defined by any one of the following: i. age ≥ 60 years old ii. underlying medical comorbidities, defined as: * serious cardiovascular disease * poorly controlled diabetes (i.e., a1c levels \>7%) * chronic kidney disease requiring dialysis * significant liver disease (pugh-child b or c) * severe obesity (body mass index \[bmi\] ≥ 40) * chronic respiratory disease (e.g., copd) * hypertension, defined as blood pressure ≥ 140 / 90 mmhg iii. solid organ or stem cell transplant recipient iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. receipt of biologic agent or prednisone \> 0.5 mg/kg/day (or equivalent) 6. patient must be within 5 days of symptom onset, as determined by clinical team. 7. participants with preexisting auditory damage are allowed. 8. participants with a history of epilepsy are allowed. 9. female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug. 10. focbp must agree to use highly-effective method(s) of contraception (appendix b) during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for \>1 year without an alternative medical cause. 11. male participants must agree to use an adequate method of contraception (appendix b) starting with the first dose of study therapy through at least 1 months after the last dose of study drug. 12. participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.

inclusion criteria: ability to understand and the willingness to sign a written informed consent document. individuals aged ≥ 18 years of all races and ethnic groups. must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov- 2 infection within the past 14 days not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s). must meet at least one of the following clinical stratifications: have at least 1 minor criterion per ats criteria (refer to appendix a), or have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography [ct]), or high risk for poor outcome, as defined by any one of the following: i. age ≥ 60 years old ii. underlying medical comorbidities, defined as: serious cardiovascular disease poorly controlled diabetes (i.e., a1c levels >7%) chronic kidney disease requiring dialysis significant liver disease (pugh-child b or c) severe obesity (body mass index [bmi] ≥ 40) chronic respiratory disease (e.g., copd) hypertension, defined as blood pressure ≥ 140 / 90 mmhg iii. solid organ or stem cell transplant recipient iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent) patient must be within 5 days of symptom onset, as determined by clinical team. participants with preexisting auditory damage are allowed. participants with a history of epilepsy are allowed. female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug. focbp must agree to use highly-effective method(s) of contraception (appendix b) during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause. male participants must agree to use an adequate method of contraception (appendix b) starting with the first dose of study therapy through at least 1 months after the last dose of study drug. participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.

inclusion criteria: ability to understand and the willingness to sign a written informed consent document. individuals aged ≥ 18 years of all races and ethnic groups. must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov- 2 infection within the past 14 days not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s). must meet at least one of the following clinical stratifications: have at least 1 minor criterion per ats criteria (refer to appendix a), or have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography [ct]), or high risk for poor outcome, as defined by any one of the following: i. age ≥ 60 years old ii. underlying medical comorbidities, defined as: serious cardiovascular disease poorly controlled diabetes (i.e., a1c levels >7%) chronic kidney disease requiring dialysis significant liver disease (pugh-child b or c) severe obesity (body mass index [bmi] ≥ 40) chronic respiratory disease (e.g., copd) hypertension, defined as blood pressure ≥ 140 / 90 mmhg iii. solid organ or stem cell transplant recipient iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent) patient must be within 5 days of symptom onset, as determined by clinical team. participants with preexisting auditory damage are allowed. participants with a history of epilepsy are allowed. female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug. focbp must agree to use highly-effective method(s) of contraception (appendix b) during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause. male participants must agree to use an adequate method of contraception (appendix b) starting with the first dose of study therapy through at least 1 months after the last dose of study drug. participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.

inclusion criteria: 1. ability to understand and the willingness to sign a written informed consent document. 2. individuals aged ≥ 18 years of all races and ethnic groups. 3. must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov- 2 infection within the past 14 days 4. not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s). 5. must meet at least one of the following clinical stratifications: 1. have at least 1 minor criterion per ats criteria (refer to appendix a), or 2. have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography [ct]), or 3. high risk for poor outcome, as defined by any one of the following: i. age ≥ 60 years old ii. underlying medical comorbidities, defined as: - serious cardiovascular disease - poorly controlled diabetes (i.e., a1c levels >7%) - chronic kidney disease requiring dialysis - significant liver disease (pugh-child b or c) - severe obesity (body mass index [bmi] ≥ 40) - chronic respiratory disease (e.g., copd) - hypertension, defined as blood pressure ≥ 140 / 90 mmhg iii. solid organ or stem cell transplant recipient iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent) 6. patient must be within 5 days of symptom onset, as determined by clinical team. 7. participants with preexisting auditory damage are allowed. 8. participants with a history of epilepsy are allowed. 9. female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug. 10. focbp must agree to use highly-effective method(s) of contraception (appendix b) during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause. 11. male participants must agree to use an adequate method of contraception (appendix b) starting with the first dose of study therapy through at least 1 months after the last dose of study drug. 12. participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.

inclusion criteria: 1. ability to understand and the willingness to sign a written informed consent document. 2. individuals aged ≥ 18 years of all races and ethnic groups. 3. must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov- 2 infection within the past 14 days 4. not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s). 5. must meet at least one of the following clinical stratifications: 1. have at least 1 minor criterion per ats criteria (refer to appendix a), or 2. have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography [ct]), or 3. high risk for poor outcome, as defined by any one of the following: i. age ≥ 60 years old ii. underlying medical comorbidities, defined as: - serious cardiovascular disease - poorly controlled diabetes (i.e., a1c levels >7%) - chronic kidney disease requiring dialysis - significant liver disease (pugh-child b or c) - severe obesity (body mass index [bmi] ≥ 40) - chronic respiratory disease (e.g., copd) - hypertension, defined as blood pressure ≥ 140 / 90 mmhg iii. solid organ or stem cell transplant recipient iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent) 6. patient must be within 5 days of symptom onset, as determined by clinical team. 7. participants with preexisting auditory damage are allowed. 8. participants with a history of epilepsy are allowed. 9. female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug. 10. focbp must agree to use highly-effective method(s) of contraception (appendix b) during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause. 11. male participants must agree to use an adequate method of contraception (appendix b) starting with the first dose of study therapy through at least 1 months after the last dose of study drug. 12. participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.

inclusion criteria: 1. ability to understand and the willingness to sign a written informed consent document. 2. individuals aged ≥ 18 years of all races and ethnic groups. 3. must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov-2 infection within the past 14 days 4. not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s). 5. must meet at least one of the following clinical stratifications: 1. have at least 1 minor criterion per ats criteria (refer to appendix a), or 2. have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography [ct]), or 3. high risk for poor outcome, as defined by any one of the following: i. age ≥ 60 years old ii. underlying medical comorbidities, defined as: - cardiovascular disease - diabetes - chronic respiratory disease (e.g., copd) - hypertension, defined as blood pressure ≥ 140 / 90 mmhg iii. solid organ or stem cell transplant recipient iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent) 6. participants with preexisting auditory damage are allowed. 7. participants with a history of epilepsy are allowed. 8. female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug. 9. focbp must agree to use highly-effective method(s) of contraception during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause. 10. male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through at least 1 months after the last dose of study drug. 11. participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.

inclusion criteria: 1. ability to understand and the willingness to sign a written informed consent document. 2. individuals aged ≥ 18 years of all races and ethnic groups. 3. must have documented positive test result for sars-cov-2 (covid19), or high clinical suspicion for sars-cov-2 based on presence of typical clinical findings (e.g., fever, respiratory symptoms, pulmonary abnormalities on chest x-ray or ct scan), lack of alternative diagnosis, and history of exposure to a known case of sars-cov-2 infection within the past 14 days 4. not receiving institutional therapy for treatment of sars-cov-2, including (but not limited to) remdesivir, chloroquine, hydroxychloroquine, or any other investigational agent(s). 5. must meet at least one of the following clinical stratifications: 1. have at least 1 minor criterion per ats criteria (refer to appendix a), or 2. have fever, respiratory symptoms, with pneumonia visible on chest imaging (e.g., x-ray or computed tomography [ct]), or 3. high risk for poor outcome, as defined by any one of the following: i. age ≥ 60 years old ii. underlying medical comorbidities, defined as: - cardiovascular disease - diabetes - chronic respiratory disease (e.g., copd) - hypertension, defined as blood pressure ≥ 140 / 90 mmhg iii. solid organ or stem cell transplant recipient iv. diagnosis of solid or hematologic malignancy being treated with systemic chemotherapy v. receipt of biologic agent or prednisone > 0.5 mg/kg/day (or equivalent) 6. participants with preexisting auditory damage are allowed. 7. participants with a history of epilepsy are allowed. 8. female participants of childbearing potential (focbp) must have a negative serum or urine pregnancy test (per institutional standards) prior to the start of study drug. 9. focbp must agree to use highly-effective method(s) of contraception during the study and for 1 months after the last dose of study drug. focbp are those who have not been surgically sterilized or have not been free from menses for >1 year without an alternative medical cause. 10. male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through at least 1 months after the last dose of study drug. 11. participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment.